Fetal RHD genotyping from maternal plasma may be used with confidence, although additional polymorphisms for confirmation of fetal DNA should be included for 100 percent predictive value (instead of 99.6%).

Nowadays, mastitis is one of the biggest problems in breeding dairy cattle. Treatment of this disease with conventional antibiotics is ineffective because many pathogens are resistant. Researchers have therefore been forced to look for new solutions, and metal nanoparticles (NPs) have been found to be the most appropriate agents. This study uses commercially available silver (AgNPs) and copper (CuNPs) nanoparticles and synthetized silver–copper nanoparticles (AgCuNPs) to evaluate the effect of these NPs on human and bovine mammary cells. The effect of AgNPs, CuNPs, and AgCuNPs on pathogen species commonly involved in udder inflammation (e.g., Staphylococcus aureus and Escherichia coli) was also established. The results show that commercially available NPs were of good quality and did not have a toxic effect on mammary gland tissue. AgNPs, CuNPs, and AgCuNPs also influenced or decreased the viability of pathogens. Therefore, the presented data suggest that metal NPs could be used in mastitis prevention and treatment in the future. However, the presented preliminary results require further in vivo analysis.

Bovine mastitis is a common bovine disease, frequently affecting whole herds of cattle. It is often caused by resistant microbes that can create a biofilm structure. The rapidly developing scientific discipline known as nanobiotechnology may help treat this illness, thanks to the extraordinary properties of nanoparticles. The aim of the study was to investigate the inhibition of biofilms created by mastitis pathogens after treatment with silver and copper nanoparticles, both individually and in combination. We defined the physicochemical properties and minimal inhibitory concentration of the nanoparticles and observed their interaction with the cell membrane, as well as the extent of biofilm reduction. The results show that the silver–copper complex was the most active of all nanomaterials tested (biofilm was reduced by nearly 100% at a concentration of 200 ppm for each microorganism species tested). However, silver nanoparticles were also effective individually (biofilm was also reduced by nearly 100% at a concentration of 200 ppm, but at concentrations of 50 and 100 ppm, the extent of reduction was lower than for the complex). Nanoparticles can be used in new alternative therapies to treat bovine mastitis.

BackgroundThe aim of this study was to investigate the association between plasma β-hydroxybutyric acid (BHBA) and conjugated linoleic acid in postpartum Polish Holstein-Friesian (PHF) cows. The experiment was carried out at an experimental dairy farm, where a herd of approximately 350 cows was kept. Samples were taken at six time points: between days 5–7, 8–14, 15–21, 22–28, 29–35, and 36–42, resulting in 510 samples of both milk and blood. The cows involved in the experiment were divided into two groups – ketotic and healthy – by taking into account general health symptoms, blood serum BHBA, and non-esterified fatty acids (NEFA) concentration at 5–7 days postpartum.ResultsIn the first week of lactation, at 5–7 day in milk (DIM), the study showed a 53% lower level of C18:2 cis-9 trans-11 (CLA9) and an 80% lower level of C18:2 trans-10 cis-12 (CLA10) in cows with diagnosed ketosis compared to healthy cows. In the second week of lactation (8–14 DIM), a 34% lower level of CLA9 and a 54% lower level of CLA10 was found in the group of cows with BHBA levels > 1.2 mmol/L. Additionally, Pearson correlation analysis showed significant negative correlation between BHBA x CLA9 and BHBA x CLA10 in the first week of lactation: − 0.732and − 0.821, respectively.ConclusionThe study shows that that both CLA9 and CLA10 can be used as markers for the early diagnosis of elevated blood levels of BHBA in postpartum Polish Holstein-Friesian cows.

Parvovirus B19 (B19V) is divided into three genotypes. Genotypes 2 and 3 may cause diagnostic difficulties and their epidemiology is not well understood. In the present study the prevalence of B19V genotypes in patients with symptomatic infection in Poland was evaluated and the course of infection in patients infected with non-genotype 1 strains is described. Real-time PCR, able to detect all three genotypes of B19V was used to screen patient plasma samples. Sixty-nine, mainly acute-phase B19V DNA positive cases were identified in patients from hematological and obstetric/gynecological wards between 2004 and 2008. Thirty patients were studied in greater detail and genotyping was performed by analysis of the NS1/VP1u region. The majority of samples were genotype 1. However two (6.6%) strains were identified as genotype 2, associated with high viremia and identified in a kidney transplant recipient with anemia and a leukemia patient, following chemotherapy, with pancytopenia. A change of immunosuppression treatment in the former and treatment with intravenous immunoglobulin in latter, resulted in normalization of clinical parameters, and whilst viral loads fell, B19V DNA was still detectable. The kidney transplant recipient subsequently became pregnant with no clinical complications, although persistently infected with B19V genotype 2. This is the first description of symptomatic cases of genotype 2 B19V infection in Eastern Europe suggesting that acute infection, particularly among immunocompromised patients with these virus strains may be more prevalent than thought.